- Our Doctors
- Dr Grant Buchanan
Dr Grant Buchanan
MD PhD BSc (Hons) FRANZCR, Radiation Oncologist
For patients/carers
For doctors
MD PhD BSc (Hons) FRANZCR, Radiation Oncologist
Locations
Clinical interests
- Gastrointestinal cancer
- Breast cancer
- Myeloma
- Lung cancer
- Non-hodgkin's lymphoma
- Prostate cancer
- CNS malignancy
Languages
Fluent
- English
Biography
Clinical interests in Breast, GI, Brain, Prostate and Lung Cancers, as well as Myeloma and Non-Hodgkin lymphoma.
Dr Grant Buchanan studied medicine at Flinders University in South Australia, graduating with an MD in 2014, and subsequently completed specialist Radiation Oncology training at The Canberra Hospital in 2025.
In addition to his clinical focus, Grant is a strong advocate for medical research and teaching, and holds a PhD in the molecular oncology of breast and prostate cancers. He has authored more than 65 scientific publications that have been cited over 6,000 times, and over 100 scientific abstracts. In 2010, Grant received the National Young Investigator of the Year Award from the Prostate Cancer Foundation of Australia.
Grant has held national research grants from the Australian Research Council, the National Health and Medical Research Council of Australia, and the Prostate Cancer Foundation of Australia. He has graduated several PhD and honours students and has a keen interest in teaching medical students and Radiation Oncology Advanced Trainees.
More information
- Fellow of The Royal Australian and New Zealand College of Radiologists (FRANZCR)
- Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., & Tilley, W. D. (2001). Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research, 7(5), 1273–1281.
- Buchanan, G., Yang, M., Cheong, A., Harris, J. M., Irvine, R. A., Lambert, P. F., Moore, N. L., Raynor, M., Neufing, P. J., Coetzee, G. A., & Tilley, W. D. (2004). Structural and functional consequences of glutamine tract variation in the androgen receptor . Human Molecular Genetics, 13(16), 1677–1692.
- Wang, Q., Tiffen, J., Bailey, C. G., Lehman, M. L., Ritchie, W., Fazli, L., Metierre, C., Feng, Y. J., Li, E., Gleave, M., Buchanan, G., Nelson, C. C., Rasko, J. E. J., & Holst, J. (2013). Targeting amino acid transport in metastatic castration-resistant prostate cancer: Effects on cell cycle, cell growth, and tumor development . Journal of the National Cancer Institute, 105(19), 1463–1473. https://doi.org/10.1093/jnci/djt241
- Leach, D. A., Need, E. F., Toivanen, R., Trotta, A. P., Palethorpe, H. M., Tamblyn, D. J., Kopsaftis, T., England, G. M., Smith, E., Drew, P. A., Pinnock, C. B., Lee, P., Holst, J., Risbridger, G. P., Chopra, S., DeFranco, D. B., Taylor, R. A., & Buchanan, G. (2015). Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome . Oncotarget, 6(18), 16135–16150. https://doi.org/10.18632/oncotarget.3873
- Need, E. F., Selth, L. A., Trotta, A. P., Leach, D. A., Giorgio, L., O’Loughlin, M. A., Smit, E., Gill, P. G., Ingman, W. V., Graham, J. D., & Buchanan, G. (2015). The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype . BMC Cancer, 15(1), 791.
Explore more
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.